Visiox Pharma announced that the FDA has accepted its new drug application (NDA) for 0.35% brimonidine tartrate (PDP-716) for the treatment of glaucoma.
What is PDP-716?
PDP-716 is a novel once-daily brimonidine formulation that uses Visiox's patented TearAct fine resin technology to provide slow, consistent, and sustained drug release for IOP control throughout the day.
When might PDP-716 be available?
The company has received a PDUFA date of August 2023. Stay tuned.